Breaking News, Trials & Filings

Trials & Filings in Brief: Jan. 13, 2014

Ampio, Galectin, Generex, Gilead, Merck, The Medicines Company

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I
Galectin completes enrollment in first NASH cohort . . . read more

Phase II
Generex completes breast cancer immunotherapy enrollment . . . read more

Phase III
Ampio begins dosing in pivotal trial . . . read more

Filings
Gilead gets PDUFA date for iNHL treatment . . . read more

Merck begins rolling BLA for PD-1 immunotherapy . . . read more

TMC antibiotic gets QIDP designation . . . read more

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters